Neutrophil-to-lymphocyte ratio and short-term mortality in patients having anti-MDA5-positive dermatomyositis with interstitial lung disease: a retrospective study by Hongxia Xin, Ping He, Bin Xi, Zhaojun Wang, Han Wang, Faxuan Wang, Zhanbing Ma, Jing Xue, Yuanyuan Jia, Hourong Cai, Bi Chen, Juan Chen

“…Abstract Background In this study, we aimed to explore the association between baseline and early changes in the neutrophil-to-lymphocyte ratio (NLR) and the 30-day mortality rate in patients having anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis with interstitial lung disease (DM-ILD). …”
Get full text

Loading of CAR‐T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism by Felix Pfister, Lucas R. Carnell, Lisa Löffler, Philipp Boosz, Niels Schaft, Jan Dörrie, René Stein, Malte Lenz, Erdmann Spiecker, Christian M. Huber, Sami Haddadin, Carola Berking, Christoph Alexiou, Christina Janko

“…SPION‐loaded CAR‐T cells maintained their specific cytolytic capacity against melanoma cells expressing the CAR‐specific antigen chondroitin sulfate proteoglycan (CSPG4). …”
Get full text

Protective Effect of Conditioned Medium of Immortalized Human Stem Cells from Exfoliated Deciduous Teeth Against Hair Graying Caused by X-Ray Irradiation via Its Antioxidative Acti... by Yasuhiro Katahira, Eri Horio, Natsuki Yamaguchi, Jukito Sonoda, Miu Yamagishi, Satomi Miyakawa, Fumihiro Murakami, Hideaki Hasegawa, Izuru Mizoguchi, Takayuki Yoshimoto

“…Consistent with these in vivo results, SHED-CM significantly inhibited the cell death caused by X-ray irradiation in melanoma cell line B16F10 cells. Immunodepletion of HGF or VEGF in the SHED-CM revealed that this inhibition was due to suppression of the generation of reactive oxygen species, which was mainly mediated by HGF and probably VEGF. …”
Get full text

Electrochemotherapy with bleomycin, oxaliplatin, or cisplatin in mouse tumor models, from tumor ablation to in situ vaccination by Katja Uršič Valentinuzzi, Katja Uršič Valentinuzzi, Urška Kamenšek, Urška Kamenšek, Simona Kranjc Brezar, Chloe Heranney, Chloe Heranney, Tilen Komel, Tilen Komel, Simon Buček, Simon Buček, Maja Čemažar, Maja Čemažar, Gregor Serša, Gregor Serša

“…By evaluating ECT’s potential for in situ vaccination, our goal was to pave the way for future advancements for its combination with emerging (immuno)therapies, leading to enhanced responses and outcomes.MethodsWe employed two mouse tumor models, the immunologically cold B16F10 melanoma and 4T1 mammary carcinoma, to explore both local and systemic (i.e., abscopal) antitumor effects following equieffective intratumoral ECT with BLM, OXA, and CDDP. …”
Get full text

Immunosuppression and Outcomes in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck by Doriana Iancu, Ana Fulga, Doina Vesa, Iuliu Fulga, Dana Tutunaru, Andrei Zenovia, Alin Ionut Piraianu, Elena Stamate, Corina Sterian, Florentin Dimofte, Mihail Alexandru Badea, Alin Laurentiu Tatu

“…Cutaneous squamous scell carcinoma (cSCC) is a frequent non-melanoma skin cancer that originates from keratinocytes with increased prevalence. cSCC can be either in situ, as in Bowen’s disease, or extended. …”
Get full text

CHAT-S study protocol: A randomized controlled trial of a health insurance literacy education program for young adult cancer survivors by Mary Killela, Cindy A. Turner, Amy Chevrier, Monique Stefanou, Perla L. Vaca Lopez, Heydon K. Kaddas, Karely M. van Thiel Berghuijs, Echo L. Warner, Giselle K. Perez, Austin R. Waters, Douglas B. Fair, Richard E. Nelson, Mark A. Lewis, Elyse R. Park, Anne C. Kirchhoff

“…We will enroll 300 YA cancer survivors (n = 200 intervention; n = 100 usual care) diagnosed with breast, testicular, lymphoma, sarcoma, colorectal, melanoma, or thyroid cancer between the ages of 26 and 39, who have completed treatment in the past two years. …”
Get full text

Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination by Zachary S Morris, Paul M Sondel, Amy K Erbe, Alexander L Rakhmilevich, Amber M Bates, Peter M Carlson, Alexander A Pieper, Ravi B Patel, Jen Birstler, Joseph Grudzinski, Reinier Hernandez, Bryan P Bednarz, Jamey P Weichert, Arika S Feils, Matthew Rodriquez, Claire Sun, Ian Marsh

“…Given the immune-stimulatory capacity of radiation therapy (RT), we hypothesized that delivering RT to all sites of disease would augment systemic antitumor responses to ISV.Methods We used a syngeneic B78 murine melanoma model consisting of a ‘primary’ flank tumor and a contralateral smaller ‘secondary’ flank tumor, treated with 12 Gy EBRT and intratumoral IC immunotherapy to the primary and additional EBRT to the secondary tumor. …”
Get full text

Transition metal-based MOFs for Fenton-like photocatalytic degradation of organic pollutants: Performance, stability, and biocompatibility by S.M. Tikhanova, Yu.A. Tishchenko, E.Yu. Stovpiaga, M. Timofeeva, D.V. Lipin, S.A. Povarov, V.A. Milichko, A.S. Timin, S.A. Shipilovskikh, V.I. Popkov

“…In vitro studies conducted on human monocytes (THP-1), murine embryonic fibroblasts (MEF-NF), breast cancer cells (4T1), melanoma cells (B16-F10), and colorectal cancer cells (CT26) demonstrated high biocompatibility of the developed MOFs. …”
Get full text

Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9 by Tao Fan, Chu Xiao, Ziqin Deng, Shuofeng Li, He Tian, Yujia Zheng, Bo Zheng, Chunxiang Li, Jie He

“…Importantly, this risk-score system showed satisfactory predictive performance for the ICB therapy responses of patients suffering from several cancer types, and we identified that SLAMF9 was one of the immunosuppressive phenotype and immunotherapy resistance-determined genes of H3K4me3-RS. The mice melanoma model showed Slamf9 knockdown remarkably restrained cancer progression and enhanced the efficacy of anti-CTLA-4 and anti-PD-L1 therapies by elevating CD8 + T cell infiltration. …”
Get full text

(<i>E</i>)-1-(3-(3-Hydroxy-4-Methoxyphenyl)-1-(3,4,5-Trimethoxyphenyl)allyl)-1<i>H</i>-1,2,4-Triazole and Related Compounds: Their Synthesis and Biological Evaluation as Novel Anti... by Gloria Ana, Azizah M. Malebari, Sara Noorani, Darren Fayne, Niamh M. O’Boyle, Daniela M. Zisterer, Elisangela Flavia Pimentel, Denise Coutinho Endringer, Mary J. Meegan

“…In addition, compound <b>22b</b> demonstrated potent activity in the sub-micromolar range against the NCI 60 cancer cell line panel including prostate, melanoma, colon, leukemia, and non-small cell lung cancers. …”
Get full text

Umbilical Cord Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles Modulate Skin Matrix Synthesis and Pigmentation by Kee LT, Foo JB, How CW, Nur Azurah AG, Chan HH, Mohd Yunus MH, Ng SN, Ng MH, Law JX

“…Additionally, the effects of UC-MSC-sEVs on the proliferation, melanin content, and tyrosinase (TYR) activity of human melanoma cells (MNT-1) were examined. Furthermore, ex vivo models were employed to evaluate the skin permeation of PKH26-labelled UC-MSC-sEVs.Results: The findings indicated that a high concentration of UC-MSC-sEVs positively influenced the proliferation of HDF. …”
Get full text

Therapeutic applications of artemisinin in ophthalmic diseases by Hao Sun, Ping Zhao, Lianghui Zhao, Zhizhong Zhao, Haoyu Chen, Cong Ren, Bin Guo

“…To better explore and perfect the mechanism of action of artemisinin in ophthalmic diseases, and to better promote the clinical application of artemisinin, this study reviews the latest progress of artemisinin treatment for uveitis, uveal melanoma, age-related macular degeneration, diabetic retinopathy, ocular neovascularization, and dry eye, and it will provide theoretical support for the large-scale application of artemisinin in ophthalmic diseases in the future.…”
Get full text

CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors by Chrystal Paulos, Mary Jo Turk, Megen C Wittling, Yina H Huang, Asmaa O Mohamed, David Tyler Boone, Shannon L Ferry, Melanie C Peck, Alicia M Santos, Haille E Soderholm

“…Here, we describe the intrinsic ability of CAR T cells to differentiate into memory T cells, the effect of cytokine armoring, and neoadjuvant CD4 depletion therapy on CAR and tumor-specific endogenous memory T cells.Methods TRP1-specific or NKG2D CAR T cells alone or with Super2+IL-33 (S233) armoring and/or CD4 depletion were evaluated in immunocompetent B16F10 melanoma or MC38 colon cell carcinoma models without preconditioning. …”
Get full text

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme by Peter Nash, Yoshiya Tanaka, Kevin L Winthrop, Eun Bong Lee, Xavier Mariette, Jeffrey R Curtis, Kenneth Kwok, Connie Chen, Pinaki Biswas, Lisy Wang, Christina Charles-Schoeman, Ann Madsen, Stanley B Cohen, Andrea Shapiro, Jürgen Wollenhaupt

“…IRs (95% CI) for malignancies (excluding non-melanoma skin cancer [NMSC]), NMSC and lymphomas were 0.8 (0.7 to 0.9), 0.6 (0.5 to 0.7) and 0.1 (0.0 to 0.1), respectively. …”
Get full text

Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy by Patrick Hwu, Ravi Murthy, Aung Naing, Sapna P. Patel, Simon Young, Alda Tam, Nina M. Muñoz, Malea Williams, Katherine Dixon, Crystal Dupuis, Amanda McWatters, Rony Avritscher, Soraya Zorro Manrique, Kevin McHugh, David Leach, Jeffrey D. Hartgerink, Punit Prakash, Rahul A. Sheth

“…Evaluation of tumor stroma on intratumoral drug delivery revealed that there was a greater than twofold improvement in intratumoral distribution in soft tumors (B16 melanoma) compared with firm tumors (MC38 colorectal).Conclusions Injection technique, drug formulation and tumor stiffness play key roles in the accurate delivery of intratumoral immunotherapeutics.…”
Get full text

Knowledge, Attitude, and Practice (KAP) Survey toward Skin Cancer among Ecuadorian Population by Victor H. Pinos-León, César Sandoval, Franklin Cabrera, Esmeraldas Terán, Ana Garnica, Ana Kellendonk, Mery Alvear, Carla Rosero, Lorena Vaca, Jorge Bonifaz, Anita Buestán, Claudia Armas, Raquel Trujillo, Patricio Freire, Tamara León, Giselle Erazo, Liliana García, Marcela Alzate, Vicente Toapanta, Myriam Ortega, Daniela Caicedo, Alicia Pereira, Lenin Gómez-Barreno, Juan S. Izquierdo-Condoy, Merry Charlie, Esteban Ortiz-Prado, Katherine Simbaña-Rivera

“…Skin cancer is one of the most common cancers, and melanoma is a highly preventable cancer. In Ecuador, few studies have evaluated the awareness levels of the population about the disease. …”
Get full text

Clinical characteristics and prognosis of amyopathic dermatomyositis patients with interstitial lung disease: insights from a retrospective cohort by Yanan Ying, Tingting Wu, Long Wang, Yun Zhang, Yiming Yu, Zaichun Deng, Qunli Ding

“…Cox multivariate analysis revealed that age (p = 0.002), smoking status (p = 0.011), anti-melanoma differentiation-associated gene 5 (MDA5) antibody (p = 0.017), and white blood cell count (p = 0.004) were independent predictors of shorter survival. …”
Get full text

Changes in cancer incidence and stage during the COVID-19 pandemic in 2020–2021 in the Nordic countries by Anna Johansson, Anna Skog, Tom Børge Johannesen, Tor Åge Myklebust, Simon M. Kønig, Charlotte Wessel Skovlund, Lina Steinrud Mørch, Søren Friis, Marnar Fríðheim Kristiansen, David Pettersson, Eva María Gudmundsdóttir, Nanna Margrét Kristinsdóttir, Helgi Birgisson, Sandra Irenaeus, Johan Ahlgren, Mats Lambe, Elli Hirvonen, Janne Pitkäniemi, Giske Ursin

“…Prostate cancer rates declined in Denmark/Finland/Norway/Sweden during 2020–2021, while melanoma rates declined in Finland in 2020. During 2020, colon cancer rates declined in Denmark and Iceland, while rectal cancer rates declined in Denmark, and lung and kidney cancer rates declined in Norway. …”
Get full text

Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes by Kazuhiro Kakimi, Hirokazu Matsushita, Masaaki Komatsu, Eiryo Kawakami, Mikako Nishida, Nahoko Yamashita, Taisaku Ogawa, Keita Koseki, Eiji Warabi, Tomoyuki Ohue, Katsuyuki Shiroguchi, Heiichiro Udono

“…RNA sequencing was performed for CD8TILs and tumor cells. Melanoma cells containing an IFN-γ receptor (IFNγR) cytoplasmic domain deletion mutant was overexpressed and used for characterization of the metabolic profile of those tumor cells using a Seahorse Flux Analyzer.Results Met administration elevates mtROS and cell surface Glut-1, resulting in the production of IFN-γ in CD8TILs. mtROS activates Nrf2 in a glycolysis-dependent manner, inducing activation of autophagy, glutaminolysis, mTORC1, and p62/SQSTM1. mTORC1-dependent phosphorylation of p62 at serine 351 (p-p62(S351)) is also involved in activation of Nrf2. …”
Get full text

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in pat... by Christy Ralph, Sumati Gupta, Matthew Zibelman, Brendan D Curti, Kevin J Harrington, Steven J O'Day, Andrew G Hill, David C Campbell, Gavin M Wright, David E Gerber, Jonathan E Rosenberg, Jaime R Merchan, Charles M Rudin, Hardev S Pandha, Wallace L Akerley, Daphne Day, Timothy D Clay, Ross R Jennens, Yixin Ren, Emmett V Schmidt, Lisa Guttman

“…This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors.Methods Patients had advanced non-small cell lung cancer (NSCLC), urothelial cancer, metastatic castration-resistant prostate cancer, or melanoma in part A (V937 monotherapy), and metastatic NSCLC or urothelial cancer in part B (V937+pembrolizumab). …”
Get full text